| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
89,424,000 |
| Market
Cap: |
1.10(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$6.07 - $20.5 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 8.3 |
| Insider 6 Months : 8.3 |
| Insider 3/6 Months : 17 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Arvinas is a biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies to degrade disease-causing proteins. Co. is developing ARV-110, a proteolysis targeting chimeras (PROTAC) targeted protein degrader targeting the androgen receptor protein for the treatment of men with metastatic castration-resistant prostate cancer. Co. is also developing ARV-471, a PROTAC targeted protein degrader targeting the estrogen receptor protein, or ER, for the treatment of patients with locally advanced or metastatic ER positive / HER2 negative breast cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
30,000 |
30,000 |
30,000 |
30,000 |
| Total Buy Value |
$227,010 |
$227,010 |
$227,010 |
$227,010 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
230 |
8,513 |
62,950 |
73,479 |
| Total Sell Value |
$2,275 |
$64,999 |
$904,577 |
$1,395,494 |
| Total People Sold |
1 |
3 |
6 |
8 |
| Total Sell Transactions |
1 |
3 |
8 |
13 |
| End Date |
2025-09-14 |
2025-06-13 |
2024-12-13 |
2023-12-14 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Loomis David K |
Chief Accounting Officer |
• – – |
2025-11-07 |
4 |
S |
$9.89 |
$2,275 |
D/D |
(230) |
31,697 |
|
-18% |
|
| Morrison Briggs |
Director |
– • – |
2025-09-22 |
4 |
B |
$7.57 |
$227,010 |
D/D |
30,000 |
76,021 |
2.39 |
67% |
|
| Agarwal Sunil |
Director |
– • – |
2025-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
16,025 |
30,166 |
|
- |
|
| Kennedy Edward Moore Jr. |
Director |
– • – |
2025-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
16,025 |
39,430 |
|
- |
|
| Morrison Briggs |
Director |
– • – |
2025-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
16,025 |
46,021 |
|
- |
|
| Cunningham Everett |
Director |
– • – |
2025-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
16,025 |
26,045 |
|
- |
|
| Young John D |
Director |
– • – |
2025-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
16,025 |
26,045 |
|
- |
|
| Norwalk Leslie V |
Director |
– • – |
2025-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
16,025 |
26,045 |
|
- |
|
| Smaldone Alsup Laurie |
Director |
– • – |
2025-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
16,025 |
26,045 |
|
- |
|
| Bain Linda |
Director |
– • – |
2025-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
16,025 |
26,045 |
|
- |
|
| Saik Andrew |
Chief Financial Officer |
• – – |
2025-06-24 |
4 |
S |
$7.61 |
$43,377 |
D/D |
(5,700) |
164,401 |
|
-28% |
|
| Cacace Angela M |
Chief Scientific Officer |
• – – |
2025-06-17 |
4 |
S |
$7.49 |
$19,347 |
D/D |
(2,583) |
154,248 |
|
-23% |
|
| Cacace Angela M |
Chief Scientific Officer |
• – – |
2025-05-09 |
4 |
A |
$0.00 |
$0 |
D/D |
59,600 |
156,831 |
|
- |
|
| Saik Andrew |
Chief Financial Officer |
• – – |
2025-05-09 |
4 |
A |
$0.00 |
$0 |
D/D |
59,600 |
170,101 |
|
- |
|
| Berkowitz Noah |
Chief Medical Officer |
• – – |
2025-05-09 |
4 |
A |
$0.00 |
$0 |
D/D |
59,600 |
169,623 |
|
- |
|
| Loomis David K |
Chief Accounting Officer |
• – – |
2025-05-09 |
4 |
A |
$0.00 |
$0 |
D/D |
11,825 |
30,688 |
|
- |
|
| Berkowitz Noah |
Chief Medical Officer |
• – – |
2025-03-18 |
4 |
S |
$8.59 |
$74,372 |
D/D |
(8,658) |
110,023 |
|
10% |
|
| Loomis David K |
Chief Accounting Officer |
• – – |
2025-02-24 |
4 |
S |
$16.75 |
$20,335 |
D/D |
(1,214) |
18,863 |
|
53% |
|
| Cacace Angela M |
Chief Scientific Officer |
• – – |
2025-02-24 |
4 |
S |
$16.55 |
$70,238 |
D/D |
(4,207) |
97,231 |
|
53% |
|
| Taylor Ian |
President, R&D |
• – – |
2025-02-24 |
4 |
S |
$16.55 |
$150,752 |
D/D |
(9,020) |
159,121 |
|
53% |
|
| Houston John G |
President and CEO |
• • – |
2025-02-24 |
4 |
S |
$16.55 |
$523,881 |
D/D |
(31,338) |
1,157,480 |
|
53% |
|
| Houston John G |
President and CEO |
• • – |
2025-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
152,000 |
1,188,681 |
|
- |
|
| Cacace Angela M |
Chief Scientific Officer |
• – – |
2025-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
49,092 |
100,944 |
|
- |
|
| Saik Andrew |
Chief Financial Officer |
• – – |
2025-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
49,092 |
110,501 |
|
- |
|
| Taylor Ian |
Chief Scientific Officer |
• – – |
2025-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
20,619 |
168,141 |
|
- |
|
215 Records found
|
|
Page 1 of 9 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.24 (1.91%) 
